Revance Therapeutics Inc (RVNC)
4.31
+0.07
(+1.65%)
USD |
NASDAQ |
Nov 14, 16:00
4.32
+0.01
(+0.23%)
After-Hours: 20:00
Revance Therapeutics Gross Profit (Annual): 159.68M for Dec. 31, 2023
Gross Profit (Annual) Chart
Historical Gross Profit (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 159.68M |
| December 31, 2022 | 80.90M |
| December 31, 2021 | 54.39M |
| December 31, 2020 | 10.56M |
| December 31, 2019 | 0.413M |
| December 31, 2018 | 3.729M |
| December 31, 2017 |
| Date | Value |
|---|---|
| December 31, 2016 | |
| December 31, 2015 | |
| December 31, 2014 | |
| December 31, 2013 | |
| December 31, 2012 | |
| December 31, 2011 | 0.552M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (Annual) Range, Past 5 Years
0.413M
Minimum
2019
159.68M
Maximum
2023
61.19M
Average
54.39M
Median
2021
Gross Profit (Annual) Benchmarks
| Recursion Pharmaceuticals Inc | 1.289M |
| Moderna Inc | 2.061B |
| Regeneron Pharmaceuticals Inc | 11.30B |
| MEI Pharma Inc | -- |
| GlycoMimetics Inc | -- |